vs
Side-by-side financial comparison of COMMERCE BANCSHARES INC (CBSH) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $475.7M, roughly 1.5× COMMERCE BANCSHARES INC). COMMERCE BANCSHARES INC runs the higher net margin — 29.8% vs 19.1%, a 10.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 11.1%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 7.1%).
Commerce Bancshares, Inc. is a regional bank holding company headquartered in Missouri, with principal offices in Kansas City and St. Louis. It is the corporate parent of Commerce Bank, which offers a diversified line of financial services, including business and personal banking, wealth management and investments through its affiliated companies.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
CBSH vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $475.7M | $708.5M |
| Net Profit | $141.6M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | — | 21.6% |
| Net Margin | 29.8% | 19.1% |
| Revenue YoY | 11.1% | 32.0% |
| Net Profit YoY | 10.5% | 15.5% |
| EPS (diluted) | $0.96 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $475.7M | — | ||
| Q4 25 | $449.4M | $708.5M | ||
| Q3 25 | $441.0M | $659.9M | ||
| Q2 25 | $445.8M | $603.3M | ||
| Q1 25 | $428.1M | $558.6M | ||
| Q4 24 | $422.1M | $536.6M | ||
| Q3 24 | $421.4M | $533.3M | ||
| Q2 24 | $414.5M | $528.1M |
| Q1 26 | $141.6M | — | ||
| Q4 25 | $140.7M | $135.1M | ||
| Q3 25 | $141.5M | $111.1M | ||
| Q2 25 | $152.5M | $90.3M | ||
| Q1 25 | $131.6M | $114.6M | ||
| Q4 24 | $136.1M | $117.0M | ||
| Q3 24 | $138.0M | $96.4M | ||
| Q2 24 | $139.6M | $88.4M |
| Q1 26 | — | — | ||
| Q4 25 | 40.8% | 21.6% | ||
| Q3 25 | 41.9% | 21.5% | ||
| Q2 25 | 44.0% | 20.9% | ||
| Q1 25 | 39.2% | 20.3% | ||
| Q4 24 | 41.2% | 23.4% | ||
| Q3 24 | 42.4% | 21.1% | ||
| Q2 24 | 43.4% | 19.9% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 31.3% | 19.1% | ||
| Q3 25 | 32.1% | 16.8% | ||
| Q2 25 | 34.2% | 15.0% | ||
| Q1 25 | 30.7% | 20.5% | ||
| Q4 24 | 32.2% | 21.8% | ||
| Q3 24 | 32.8% | 18.1% | ||
| Q2 24 | 33.7% | 16.7% |
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.86 | $4.65 | ||
| Q3 25 | $1.06 | $3.86 | ||
| Q2 25 | $1.14 | $3.10 | ||
| Q1 25 | $0.98 | $3.67 | ||
| Q4 24 | $0.83 | $3.67 | ||
| Q3 24 | $1.01 | $3.01 | ||
| Q2 24 | $1.03 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3B | $459.1M |
| Total Assets | $35.7B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | — | $669.4M | ||
| Q3 24 | — | $656.9M | ||
| Q2 24 | — | $510.9M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $3.8B | $459.1M | ||
| Q3 25 | $3.8B | $293.6M | ||
| Q2 25 | $3.6B | $172.4M | ||
| Q1 25 | $3.5B | $593.6M | ||
| Q4 24 | $3.3B | $825.5M | ||
| Q3 24 | $3.4B | $881.4M | ||
| Q2 24 | $3.1B | $763.6M |
| Q1 26 | $35.7B | — | ||
| Q4 25 | $32.9B | $2.0B | ||
| Q3 25 | $32.3B | $1.8B | ||
| Q2 25 | $32.3B | $1.6B | ||
| Q1 25 | $32.4B | $1.9B | ||
| Q4 24 | $32.0B | $2.1B | ||
| Q3 24 | $31.5B | $2.1B | ||
| Q2 24 | $30.6B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $645.1M | $192.7M | ||
| Q3 25 | $129.0M | $246.2M | ||
| Q2 25 | $111.2M | $148.5M | ||
| Q1 25 | $138.6M | $125.8M | ||
| Q4 24 | $577.9M | $190.7M | ||
| Q3 24 | $431.7M | $149.1M | ||
| Q2 24 | $147.4M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $592.4M | $188.1M | ||
| Q3 25 | $113.3M | $235.5M | ||
| Q2 25 | $100.5M | $142.4M | ||
| Q1 25 | $126.0M | $115.8M | ||
| Q4 24 | $531.7M | $183.0M | ||
| Q3 24 | $419.1M | $138.5M | ||
| Q2 24 | $138.9M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 131.8% | 26.6% | ||
| Q3 25 | 25.7% | 35.7% | ||
| Q2 25 | 22.5% | 23.6% | ||
| Q1 25 | 29.4% | 20.7% | ||
| Q4 24 | 126.0% | 34.1% | ||
| Q3 24 | 99.5% | 26.0% | ||
| Q2 24 | 33.5% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 0.6% | ||
| Q3 25 | 3.6% | 1.6% | ||
| Q2 25 | 2.4% | 1.0% | ||
| Q1 25 | 2.9% | 1.8% | ||
| Q4 24 | 10.9% | 1.4% | ||
| Q3 24 | 3.0% | 2.0% | ||
| Q2 24 | 2.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.59× | 1.43× | ||
| Q3 25 | 0.91× | 2.22× | ||
| Q2 25 | 0.73× | 1.65× | ||
| Q1 25 | 1.05× | 1.10× | ||
| Q4 24 | 4.25× | 1.63× | ||
| Q3 24 | 3.13× | 1.55× | ||
| Q2 24 | 1.06× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBSH
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
